Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Turner

Showing results (111-120 of 138) with videos related to

Pageof 14
Sort By:
The Lancet. Oncology|December 5, 2024
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.
Health Technology Assessment (Winchester, England)|May 15, 2014
Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trialNicola Wiles, Laura Thomas, Anna Abel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2024
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)Nicholas Turner, Cristina Saura, Philippe Aftimos, et al.
BMJ Open|April 5, 2022
Gatekeeper training for vendors to reduce pesticide self-poisoning in rural South Asia: a study protocol for a stepped-wedge cluster randomised controlled trialManjula Weerasinghe, Melissa Pearson, Nicholas Turner, et al.
Health Technology Assessment (Winchester, England)|November 24, 2021
Immediate oral versus immediate topical versus delayed oral antibiotics for children with acute otitis media with discharge: the REST three-arm non-inferiority electronic platform-supported RCTAlastair D Hay, Michael V Moore, Jodi Taylor, et al.
European Journal of Cancer (Oxford, England : 1990)|November 17, 2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 studyPeter Schmid, Oleg Lipatov, Seock-Ah Im, et al.
The Lancet. Neurology|October 23, 2021
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trialPatrick Gavin Kehoe, Nicholas Turner, Beth Howden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2018
The Spatiotemporal Evolution of Lymph Node Spread in Early Breast CancerPeter Barry, Alexandra Vatsiou, Inmaculada Spiteri, et al.
Open Forum Infectious Diseases|August 12, 2022
Clinical Features and Treatment Outcomes of Pulmonary <i>Mycobacterium avium-intracellulare</i> Complex With and Without CoinfectionsGrace Wang, Jack T Stapleton, Arthur W Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast CancerÁngel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, et al.
Pageof 14

Showing results (111-120 of 138) with videos related to

Sort By:
Pageof 14
The Lancet. Oncology|December 5, 2024
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.
Health Technology Assessment (Winchester, England)|May 15, 2014
Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trialNicola Wiles, Laura Thomas, Anna Abel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2024
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)Nicholas Turner, Cristina Saura, Philippe Aftimos, et al.
BMJ Open|April 5, 2022
Gatekeeper training for vendors to reduce pesticide self-poisoning in rural South Asia: a study protocol for a stepped-wedge cluster randomised controlled trialManjula Weerasinghe, Melissa Pearson, Nicholas Turner, et al.
Health Technology Assessment (Winchester, England)|November 24, 2021
Immediate oral versus immediate topical versus delayed oral antibiotics for children with acute otitis media with discharge: the REST three-arm non-inferiority electronic platform-supported RCTAlastair D Hay, Michael V Moore, Jodi Taylor, et al.
European Journal of Cancer (Oxford, England : 1990)|November 17, 2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 studyPeter Schmid, Oleg Lipatov, Seock-Ah Im, et al.
The Lancet. Neurology|October 23, 2021
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trialPatrick Gavin Kehoe, Nicholas Turner, Beth Howden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2018
The Spatiotemporal Evolution of Lymph Node Spread in Early Breast CancerPeter Barry, Alexandra Vatsiou, Inmaculada Spiteri, et al.
Open Forum Infectious Diseases|August 12, 2022
Clinical Features and Treatment Outcomes of Pulmonary <i>Mycobacterium avium-intracellulare</i> Complex With and Without CoinfectionsGrace Wang, Jack T Stapleton, Arthur W Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast CancerÁngel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, et al.
Pageof 14